argenx N.V. is having to take a gradual approach to growing Vyvgart sales as the generalized myasthenia gravis (gMG) product faces hurdles from the COVID-19 pandemic and the lack of medical education on the drug’s target, FcRn.
Argenx Takes Slow But Steady Approach To Vyvgart Sales
Amid Pandemic-Related And Educational Blocks
Despite a US approval for its novel FcRn inhibitor Vyvgart in gMG, the firm has realistic expectations of sales, factoring in concerns about COVID-19 and lagging medical education.
